TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07516093: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Sponsor: Nurix Therapeutics, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 620 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07516093 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07516093 Rescue Dossier →